Table 1. Enrolled patients in first-in-human phase 1 clinical trial of LUM015.
Imaging time was measured as the number of hours elapsed between LUM015 injection and imaging of the resected tissues with the LUM device. Histological descriptors are based on clinical surgical pathology reports. ER, estrogen receptor; PR, progesterone receptor; RT, radiation therapy.
| Patient | LUM015 dose (mg/kg) | Imaging time (hours) | Tumor type | Tumor grade | Tumor volume (cm3) | Neoadjuvant therapy | Tumor site |
|---|---|---|---|---|---|---|---|
| 1 | 0.5 | 30.1 | Well-differentiated liposarcoma | Low | 10.5 × 8.5 × 6.2 | None | Retroperitoneal |
| 2 | 0.5 | 28.5 | UPS | High | 13.5 × 8.3 × 6.5 | 25 × 2 Gy RT | Thigh |
| 3 | 0.5 | 28.5 | UPS | High | 18.0 × 9.0 × 6.0 | 25 × 2 Gy RT | Upper arm |
| 4 | 1.0 | 30.9 | Malignant peripheral nerve sheath tumor | Intermediate | 2.5 × 1.6 × 1.5 | 25 × 2 Gy RT | Upper arm |
| 5 | 1.0 | 26.9 | Myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor | Low | 31.0 × 20.0 × 1.3 | None | Leg |
| 6 | 1.0 | 26.5 | UPS | High | 3.6 × 2.9 × 1.2 | None | Upper arm |
| 7 | 1.0 | 4.8 | Metastatic clear cell sarcoma | High | 4.0 × 2.9 × 2.8 | None | Inguinal lymph node |
| 8 | 1.0 | 7.2 | UPS | High | 13.0 × 6.5 × 7.1 | 25 × 2 Gy RT | Upper arm |
| 9 | 1.0 | 8.3 | IDC: ER+/PR−/Her2+ | High | 3.7 | None | Breast |
| 10 | 1.5 | 9.6 | IDC: ER+/PR+/Her2− | Intermediate | 7.5 × 2.5 ×1.5 | None | Breast |
| 11 | 1.5 | 5.1 | Metastatic spindle cell sarcoma | Low | 0.9 | None | Thigh |
| 12 | 1.5 | 7.3 | Myxofibrosarcoma | High | 11.0 × 6.5 × 6.5 | None | Thigh |
| 13 | 0.5 | 9.6 | Synovial sarcoma | High | 20.0 × 12.0 × 6.0 | 25 × 2 Gy RT | Thigh |
| 14 | 0.5 | 8.5 | Spindle cell sarcoma | High | 7.5 | 25 × 2 Gy RT | Thigh |
| 15 | 0.5 | 7.3 | IDC: ER+, PR+, Her2− | High | 2.4 × 1.6 × 1.4 | None | Breast |